# Sofosbuvir + velpatasvir



## General description

A fixed-dose combination regimen of the direct acting antiviral agents sofosbuvir and velpatasvir for the treatment of genotypes 1-6 chronic hepatitis C virus (HCV) infection.

| | |
|---|---|
| **INN** | Sofosbuvir + velpatasvir |
| **ATC codes** | J05AP55 |
| **Medicine type** | Chemical agent |
| **EML status history** | First added in 2017 (TRS 1006) for Chronic hepatitis C |
| **Wikipedia** | Sofosbuvir + velpatasvir |
| **DrugBank** | Sofosbuvir, Velpatasvir |

## Recommendations

**Section** Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

**Indications**

Chronic hepatitis C